Clinical trial · Interventional
Treatment of Disseminated High Grade Lymphoma
Phase III Study of Treatment of Disseminated and Agressive Lymphoma R CHOP Versus R CLOP( With Liposomal Doxorubicin)
NCT00536393CI-TRIAL-00000938completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Interest of the use of pegylated liposomal doxorubicin (caélyx)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Doxorubicin pegylated | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Doxorubicine
- description
- CHOP 8 courses every 21 days
- interventionNames
- Drug: Doxorubicin
- type
- EXPERIMENTAL
- label
- Doxorubicine pegylated
- description
- CLOP 8 courses every 21 days
- interventionNames
- Drug: Doxorubicin pegylated
Primary outcomes (1)
- measure
- hematologic toxicity
- timeFrame
- 6 months
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * high grade lymphoma * disseminated * \> 60 years old and \< 75 * informed consent signed * cardiac state compatible with antracyclin * ECOG \</= 2 Exclusion Criteria: * patients \> 75 years old * Cardiac insufficiency
References
Publications (0)
Data not yet available
No reference posted for this study.